Mira Pharmaceuticals Q2 2026 net loss narrows to $1.21 million; revenue remains no revenue
MIRA•Operating expenses decline as R&D rises
Operating expenses fell to $1.16 million from $1.55 million, as general and administrative costs dropped to $450,330.
Research and development spending rose to $705,789 from $496,197, while interest income increased to $35,130 from $8,623.
Q2 loss narrows, with no revenue reported
Mira Pharmaceuticals posted a net loss of $1.21 million for the quarter ended June 30, 2026, narrowing from $1.54 million.
Loss per share improved to $0.03 from $0.09, with no revenue reported in either period.
Pipeline updates on Ketamir-2, MIRA-55 and SKNY-1
Ketamir-2 completed Phase 1 dosing; the Phase 2a CIPN trial is targeted for Q1 2027.
MIRA-55 and SKNY-1 advanced toward IND-enabling work.
